Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 4, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	352	364	822	830	663	1,255
Market Cap Growth	3.88%	-55.72%	-1.00%	25.14%	-47.13%	870.89%
Enterprise Value	438	435	881	865	686	1,270
Last Close Price	0.22	0.27	0.70	0.78	0.70	1.52
PE Ratio	-	-	-	-	3.70	-
PS Ratio	375.54	263.35	425.38	493.23	660.04	971.84
PB Ratio	-3.69	-4.61	-17.47	-7.90	-5.35	-3.46
EV/Sales Ratio	-	314.92	455.93	513.96	682.10	983.37
Debt / Equity Ratio	-0.81	-0.85	-0.97	-0.25	-0.31	-0.05
Net Debt / Equity Ratio	-0.76	-0.83	-0.92	-0.18	-0.18	-0.03
Net Debt / EBITDA Ratio	-1.15	-1.01	-0.80	-0.29	-0.43	-0.11
Net Debt / FCF Ratio	-1.42	-1.12	-0.76	-0.35	-0.51	-0.25
Asset Turnover	0.03	0.05	0.07	0.05	0.03	0.06
Quick Ratio	0.05	0.03	0.05	0.06	0.11	0.03
Current Ratio	0.08	0.06	0.09	0.08	0.13	0.04
Return on Assets (ROA)	-135.38%	-152.28%	-117.23%	-117.48%	-90.17%	-248.63%
Return on Capital Employed (ROCE)	113.30%	160.10%	320.10%	71.00%	56.30%	24.80%
Earnings Yield	-25.92%	-23.02%	-7.62%	-12.65%	27.00%	-42.23%
FCF Yield	-14.45%	-15.95%	-6.94%	-6.71%	-6.68%	-3.08%
Buyback Yield / Dilution	-16.16%	-10.99%	-10.17%	-0.79%	-38.99%	-28.53%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.